Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by ß1 integrins
Sarah M. Short1,
Alexandrine Derrien1,
Radha P. Narsimhan5,
Jack Lawler4,
Donald E. Ingber1,3, , and
Bruce R. Zetter1,2
1 Vascular Biology Program, Children's Hospital 2 Department of Cell Biology, Harvard Medical School, Boston, MA 02115 3 Department of Pathology, Harvard Medical School, Boston, MA 02115 4 Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115 5 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115
Correspondence to Bruce R. Zetter: bruce.zetter{at}childrens.harvard.edu
Abstract:
The anti-angiogenic effect of thrombospondin-1 has been shownto be mediated through binding of the type-1 repeat (TSR) domainto the CD36 transmembrane receptor. We now report that the TSRdomain can inhibit VEGF-induced migration in human umbilicalvein endothelial cells (HUVEC), cells that lack CD36. Moreover,we identified ß1 integrins as a critical receptorin TSR-mediated inhibition of migration in HUVEC. Using pharmacologicalinhibitors of downstream VEGF receptor effectors, we found thatphosphoinositide 3-kinase (PI3k) was essential for TSR-mediatedinhibition of HUVEC migration, but that neither PLC nor Aktwas necessary for this response. Furthermore, ß1 integrinswere critical for TSR-mediated inhibition of microvascular endothelialcells, cells that express CD36. Together, our results indicatethat ß1 integrins mediate the anti-migratory effectsof TSR through a PI3k-dependent mechanism.
Abbreviations used in this paper: EBM, endothelial basal medium;HMVEC, human microvascular endothelial cells; HSA, horse serumalbumin; HUVEC, human umbilical vein endothelial cells; IAP/CD47,integrin-associated protein; PI3k, phosphoinositide 3-kinase;RGD, Arg-Gly-Asp; siRNA, small interfering RNA; TSP1, thrombospondin-1;TSR, type-1 repeat.
The editors suggest the following Related Resources on Science sites:
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.
O. Straume, T. Shimamura, M. J. G. Lampa, J. Carretero, A. M. Oyan, D. Jia, C. L. Borgman, M. Soucheray, S. R. Downing, S. M. Short, et al. (2012)
PNAS
109, 8699-8704
|Abstract »|Full Text »|PDF »
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2.
P. R. Lawler and J. Lawler (2012)
Cold Spring Harb Perspect Med
2, a006627
|Abstract »|Full Text »|PDF »
Matricellular Proteins in Cardiac Adaptation and Disease.
Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension.
J. P. Maloney, R. S. Stearman, T. M. Bull, D. W. Calabrese, M. L. Tripp-Addison, M. J. Wick, U. Broeckel, I. M. Robbins, L. A. Wheeler, J. D. Cogan, et al. (2012)
Am J Physiol Lung Cell Mol Physiol
302, L541-L554
|Abstract »|Full Text »|PDF »
p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers.
P. Sundaram, S. Hultine, L. M. Smith, M. Dews, J. L. Fox, D. Biyashev, J. M. Schelter, Q. Huang, M. A. Cleary, O. V. Volpert, et al. (2011)
Cancer Res.
71, 7490-7501
|Abstract »|Full Text »|PDF »
Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.
S. Kazerounian, M. Duquette, M. A. Reyes, J. T. Lawler, K. Song, C. Perruzzi, L. Primo, R. Khosravi-Far, F. Bussolino, I. Rabinovitz, et al. (2011)
Blood
117, 4658-4666
|Abstract »|Full Text »|PDF »
Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties.
D. M. Smadja, C. d'Audigier, I. Bieche, S. Evrard, L. Mauge, J.-V. Dias, J. Labreuche, I. Laurendeau, B. Marsac, B. Dizier, et al. (2011)
Arterioscler Thromb Vasc Biol
31, 551-559
|Abstract »|Full Text »|PDF »
Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47.
S. Kaur, G. Martin-Manso, M. L. Pendrak, S. H. Garfield, J. S. Isenberg, and D. D. Roberts (2010)
J. Biol. Chem.
285, 38923-38932
|Abstract »|Full Text »|PDF »
Microfibrils and fibrillin-1 induce integrin-mediated signaling, proliferation and migration in human endothelial cells.
B. Mariko, Z. Ghandour, S. Raveaud, M. Quentin, Y. Usson, J. Verdetti, P. Huber, C. Kielty, and G. Faury (2010)
Am J Physiol Cell Physiol
299, C977-C987
|Abstract »|Full Text »|PDF »
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.
A. Zaslavsky, K.-H. Baek, R. C. Lynch, S. Short, J. Grillo, J. Folkman, J. E. Italiano Jr, and S. Ryeom (2010)
Blood
115, 4605-4613
|Abstract »|Full Text »|PDF »
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.
X. Zhang, S. Kazerounian, M. Duquette, C. Perruzzi, J. A. Nagy, H. F. Dvorak, S. Parangi, and J. Lawler (2009)
FASEB J
23, 3368-3376
|Abstract »|Full Text »|PDF »
Selective Activity Against Proliferating Tumor Endothelial Cells by CVX-22, A Thrombospondin-1 Mimetic CovX-BodyTM.
J. CORONELLA, L. LI, K. JOHNSON, S. PIRIE-SHEPHERD, G. ROXAS, and N. LEVIN (2009)
Anticancer Res
29, 2243-2252
|Abstract »|Full Text »|PDF »
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina.
J. Sun, B. D. Hopkins, K. Tsujikawa, C. Perruzzi, I. Adini, R. Swerlick, P. Bornstein, J. Lawler, and L. E. Benjamin (2009)
Am J Physiol Heart Circ Physiol
296, H1344-H1351
|Abstract »|Full Text »|PDF »
Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype.
N. Almog, L. Ma, R. Raychowdhury, C. Schwager, R. Erber, S. Short, L. Hlatky, P. Vajkoczy, P. E. Huber, J. Folkman, et al. (2009)
Cancer Res.
69, 836-844
|Abstract »|Full Text »|PDF »
Counterbalancing Forces: What Is Thrombospondin-1 Doing in Atherosclerotic Lesions?.
O. I. Stenina and E. F. Plow (2008)
Circ. Res.
103, 1053-1055
|Full Text »|PDF »
Cyclic Stretch Affects Pulmonary Endothelial Cell Control of Pulmonary Smooth Muscle Cell Growth.
C. D. Ochoa, H. Baker, S. Hasak, R. Matyal, A. Salam, C. A. Hales, W. Hancock, and D. A. Quinn (2008) 39, 105-112
|Abstract »|Full Text »|PDF »
Antimigratory effect of TK1-2 is mediated in part by interfering with integrin {alpha}2{beta}1.
H.-K. Kim, D.-S. Oh, S.-B. Lee, J.-M. Ha, and Y. A. Joe (2008)
Mol. Cancer Ther.
7, 2133-2141
|Abstract »|Full Text »|PDF »
Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels.
C. Brostjan, K. Gebhardt, B. Gruenberger, V. Steinrueck, H. Zommer, H. Freudenthaler, S. Roka, and T. Gruenberger (2008)
Clin. Cancer Res.
14, 2065-2074
|Abstract »|Full Text »|PDF »
Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis.
O. Fainaru, A. Adini, O. Benny, I. Adini, S. Short, L. Bazinet, K. Nakai, E. Pravda, M. D. Hornstein, R. J. D'Amato, et al. (2008)
FASEB J
22, 522-529
|Abstract »|Full Text »|PDF »
Thrombospondins Use the VLDL Receptor and a Nonapoptotic Pathway to Inhibit Cell Division in Microvascular Endothelial Cells.
A. Oganesian, L. C. Armstrong, M. M. Migliorini, D. K. Strickland, and P. Bornstein (2008)
Mol. Biol. Cell
19, 563-571
|Abstract »|Full Text »|PDF »
HIV Protease Inhibitors Enhance the Efficacy of Irradiation.
K. C. Cuneo, T. Tu, L. Geng, A. Fu, D. E. Hallahan, and C. D. Willey (2007)
Cancer Res.
67, 4886-4893
|Abstract »|Full Text »|PDF »
Targeting CD47: NO Limit on Therapeutic Potential.
D. J. Kaczorowski and T. R. Billiar (2007)
Circ. Res.
100, 602-603
|Full Text »|PDF »
CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1.
J. S. Isenberg, L. A. Ridnour, J. Dimitry, W. A. Frazier, D. A. Wink, and D. D. Roberts (2006)
J. Biol. Chem.
281, 26069-26080
|Abstract »|Full Text »|PDF »
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity.
R. M. Tjin Tham Sjin, R. Satchi-Fainaro, A. E. Birsner, V.M. S. Ramanujam, J. Folkman, and K. Javaherian (2005)
Cancer Res.
65, 3656-3663
|Abstract »|Full Text »|PDF »